Open AccessEfficacy of Tocilizumab vs. NSAIDs in the Treatment of Juvenile Rheumatoid Arthritis
Author(s) -
Daniela I. Sánchez
Publication year - 2022
Publication title -
international journal of medical science and clinical research studies
Language(s) - English
Resource type - Journals
eISSN - 2767-8342
pISSN - 2767-8326
DOI - 10.47191/ijmscrs/v2-i4-02
Subject(s) - tocilizumab , rheumatoid arthritis , medicine , monoclonal antibody , biological drugs , receptor , cytokine , monoclonal , pharmacology , humanized antibody , arthritis , cytokine receptor , interleukin 6 receptor , interleukin 6 , antibody , immunology
Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptors, both the soluble receptor (sIL-6R) and the one located in the cell membrane. In this way it blocks the molecular complex of the receptor and prevents cytokine signaling. It is a drug which has recently been approved by the FDA, several studies recently carried out at international level (USA, Japan, Europe) have demonstrated the great efficacy of tocilizumab in the treatment of juvenile rheumatoid arthritis.